source
- J&J shares fall 3% as oncology sales miss forecasts, while AstraZeneca invests $600M in lung cancer drugJohnson & Johnson’s stock slipped about 3% on Wednesday even though the company raised its full‑year sales outlook. In its latest quarterly earnings release the firm said revenue in its innovative…
- FDA acting commissioner says Makary’s journal policies are not official guidance; UK regulator reports rise in drug approvals and AI stepsThe acting commissioner of the U.S. Food and Drug Administration clarified that the policies published in medical journals by former commissioner Marty Makary do not constitute official FDA policy…